Three with­drawals in ad­vanced ovar­i­an can­cer spell trou­ble for PARP class

When As­traZeneca and Mer­ck’s PARP in­hibitor Lyn­parza was ap­proved for ad­vanced ovar­i­an can­cer back in 2014, FDA’s cur­rent On­col­o­gy Cen­ter of Ex­cel­lence di­rec­tor Richard Paz­dur …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER